Pre-emptive <i>CYP2C19</i> genotyping and voriconazole exposure in pediatric hematology patients at risk of aspergillosis: an exploratory randomized pilot study with a cost-consequence analysis.

Front Pharmacol · 2026 · PMC13433745 · PMID 42553256

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

The modified Intention-to-Treat (mITT) ( Ashbee et al., 2014 ) analysis demonstrated a positive trend in target attainment, with the Experimental group achieving a success rate of 37.5% (6/16) compared to only 12.5% (2/16) in the Control group.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Pre-emptive &lt;i&gt;CYP2C19&lt;/i&gt; genotyping and voriconazole exposure in pediatric hematology patients at risk of aspergillosis: an exploratory randomized pilot study with a cost-consequence analysis.

The sentences

Pre-emptive <i>CYP2C19</i> genotyping and voriconazole exposure in pediatric hematology patients at risk of aspergillosis: an exploratory randomized pilot study with a cost-consequence analysis.